Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Subscribe To Our Newsletter & Stay Updated
